ClinicalTrials.gg
Sign In

Dilatation, Pathologic clinical trials

The registry lists 120 studies for Dilatation, Pathologic across more than 10 countries. 18 are recruiting or about to start. 45 of them are mainly about Dilatation, Pathologic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-02.

Get an email when these change. Save the Dilatation, Pathologic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
65
Status unknown
19
Recruiting
13
Terminated
8
Withdrawn
5
Not yet recruiting
4

Phase

Phase 3
20
Phase 2
13
Phase 4
10
Early Phase 1
4
Phase 1
4

Where

United States
61
Turkey
9
Egypt
6
China
4
Italy
4
United Kingdom
3

Who runs them

Stanford University (5) · Cxlusa (4) · Sohag University (4) · Opus Genetics, Inc (4) · Assiut University (3) · University of California, San Diego (3) · Glaukos Corporation (3) · Novartis Pharmaceuticals (2)

What is being tested here

Drugs under test in Dilatation, Pathologic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Oxytocin102
Ketorolac101
Tranexamic Acid101
Diphenhydramine111
Riboflavin047
Misoprostol015
Phentolamine034
Mifepristone003
Lidocaine002
Octreotide002

Coming up

1phase 3 study under way
9studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 13 Dilatation, Pathologic studies recruiting now, 7 (54%) set no upper age limit and 4 (31%) stop at 75 or younger. 1 (8%) take children under 18. 6 (46%) are for women only and 0 (0%) for men only; 3 (23%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
100 (0%)0 (0%)
1812 (92%)6 (46%)
3013 (100%)7 (54%)
4013 (100%)7 (54%)
5013 (100%)7 (54%)
6512 (92%)7 (54%)
7510 (77%)5 (38%)
857 (54%)2 (15%)

Across all 120 studies, recruiting or not: 34% stop at 75 or younger and 28% at 65; 29% take children; 32% are for women only and 0% for men only; 30% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dilatation, Pathologic studies take

Of 27 interventional studies with no phase under Dilatation, Pathologic, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase24 mo7–37 · 27 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 120. Browse all 120 → or search them.